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Abstract 
Thennoluminescent detectors (TLD-700) have been investigated for absorbed 
dose measurements in a p(66)/Be neutron therapy beam at the National 
Accelerator Centre. Chips were selected based on their reproducibility and chip 
individual neutron calibration factors were derived. The dose non-linearity was 
detennined in peak 5 and peak 6 and dose non-linearity corrections were 
perfonned. The sensitivity of TLD-700 chips with depth and off-axis distance 
was detennined. In-vivo dose measurements were perfonned on seven patients 
(9 fields). In the entrance in-vivo dose measurements, a maximal deviation of 
3.2 % was detected and a systematic difference of 1.7 % was observed. On the 
exit side, a maximal deviation of -7.3 % was detected and a systematic 
difference of -5.1 % was observed. The glow curve peak 6/5 ratio was 
investigated and found to correlate with the qualitative variations of the 
average LET in the neutron beam. 
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Chapter 1: Introduction 
1.1 Introduction to the project 
The use of radiation in the treabnent of cancer patients relies on the precise and 
accurate delivery of the prescribed radiation dose to the designated planning 
target volume. A variety of quality assurance procedures are routinely employed 
to guarantee the proper operation and utilisation of the equipment and to ensure 
the safe delivery of the radiation dose. In addition, the measurement of the actual 
dose received by the patient during treabnent can be used as an ultimate check of 
the whole treabnent planning and delivery chain. This procedure, known as in-
vivo dosimetry, can detect errors that may otherwise be unnoticed. For example. 
Leunens et ai. (1990) detected inaccuracies in the planning algorithm and the 
dosimetry procedures after implementing an extensive in-vivo dosimetry 
program. In addition, errors in the patient positioning and the set-up of treabnent 
parameters were detected in this study. The implementation of in-vivo dosimetry 
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is therefore a worthwhile addition to any quality assurance program and can 
increase the confidence level of radiotherapy procedures. 
At the National Accelerator Centre (NAC), near Cape Town, patients are 
routinely treated at a p( 66)lBe fast neutron therapy facility. The accuracy and 
precision requirements for neutron therapy match those for photon therapy 
(Mijnheer et al., 1987) and similar quality assurance procedures are 
recommended. Thus far, in vivo dosimetry is not employed at the neutron therapy 
facility and it is the aim of this project to develop and implement this procedure 
at the NAC neutron therapy facility. 
Initial measurements were performed to establish the feasibility of using LiF 
thermoluminescent dosimeters (TLD-700) to determine the absorbed dose in 
phantom. In vivo dosimetry was then performed on several patients where 
entrance and exit doses were measured. Results were compared to the calculated 
absorbed doses according to the treatment plan. Furthermore, glow curve analysis 
was used to characterise the relative response of glow curve peak. 6 to that of 
peak. 5. This glow curve peak ratio is known to depend on the linear energy 
transfer (LET) (Noll et al., 1997). The variation of peak. 6 to peak. 5 ratio was 
investigated in our neutron beam and compared to expected qualitative changes 
in the beam. The remainder of this chapter will introduce in-vivo dosimetry, 
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neutron therapy, thermoluminescent dosimetry m general, and 
thennoluminescent dosimetry for in-vivo measurements in neutron therapy. 
1.2 In- vivo dosimetry 
Radiotherapy treatment techniques require a series of stages ranging from basic 
dosimetry over tumour localisation, treatment planning, and dose calculation to 
the daily irradiation of the patient with multiple fields. Each step involved is 
subject to a certain degree of uncertainty that can lead to possible discrepancies 
between the prescribed and the delivered dose. To minimise errors in each step, 
quality control procedures are required. In-vivo dosimetry is often an integral 
part of the quality control program since it allows a comparison of the treatment 
plan dose with the actual absorbed dose received by the patient. 
According to ICRU Report 24 (1976), in-vivo dosimetry can be divided into 
three categories: entrance dose, exit dose and intra-cavitary or organ dose 
measurements. Entrance dose measurements can be used to check the patient set-
up, beam parameters and the machine output performance. Entrance dose 
measurements allow the comparison of the planned dose with the actual 
delivered dose. It is usually performed on the patient skin with suitable build up 
material. Exit dose measurements can be used to perform similar checks and can 
give information about the treatment planning accuracy. These measurements are 
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usually perfonned on the patient skin on the central axis of the beam exit. futra-
cavitary and organ dose measurements can be perfonned on the accessible 
structures of the body to check that the received dose is in agreement with the 
calculated dose. futra-cavitary in-vivo dosimetry has been perfonned at many 
sites of the human body such as mouth, oesophagus, uterus, cervix and the 
rectum (Cameron, 1968). 
Various dosimetric methods are available for in-vivo dosimetry. Most in-vivo 
dosimetry is perfonned either with diodes or with TLDs. Semiconductor diodes 
(Alex et al., 1999) are widely used as in vivo dosimeters. The advantages of 
using semiconductor diodes are their small physical size, the ease of handling, 
and the ability to give an online readout. A disadvantage is that cables need to be 
attached to the diodes. 
Thennoluminescent dosimeters are a widely used and versatile tool for the 
assessment of dose from ionising radiation. fu photon beam dosimetry, they have 
been used widely to measure entrance and exit doses on patients for localised 
(Loncol et al., 1996) and whole body irradiations (Arnor et al., 1998). The small 
physical size and the fact that no cables or auxiliary apparatus is required during 
irradiation allow their use in many sites of the body. fu-vivo dosimetry with 
ionisation chambers has been perfonned by Heukelom et al. (1991). The 
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disadvantages of this method are the large physical size of the ionisation chamber 
and the need to supply high voltage. 
In neutron therapy dosimetry, various methods have been used for in-vivo 
dosimetry. The use of silicon diodes for in-vivo dosimetry in neutron therapy 
beams was investigated by Smith et al. (1977) and Page et al. (1984) in d(50)/Be 
and d(16)/Be beams respectively. The sensitivity of the diodes depends on the 
neutron spectrum and the accumulated dose. Corrections for temperature 
dependence at readout and fading need to be implemented. Only part of the 
radiation damage can be reversed by annealing the diode, which limits their re-
usability. However, after applying the required corrections, both studies 
concluded that the silicon diodes could be used to measure the neutron dose with 
a precision of 5 %. 
In-vivo dose measurement using 27Mg activity induced in small pellets of 
aluminium has been perfonned by Field et al. (1984) for intra-cavitary dose 
measurements using a d(14)/T neutron beam. The method was tested in a 
phantom and was later used as a routine check of the dose distribution in clinical 
trials. The results were in agreement with ionisation chamber measurements. 
Blake et al. (1990) investigated the use of TLD and activation detectors for in-
vivo dosimetry in a p(62)/Be fast neutron therapy beam. They found that the 
fonner provides a more accurate estimation of the total absorbed dose in a high-
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energy neutron beam. In-vivo dosime1ly using CaS04 TLD dosimeters has been 
performed by Blum el al. (1976), on patients treated with a d(16)lBe neutron 
beam. 
1.3 Neutron therapy 
1.3.1 Rationale 
Neutrons are indirectly ionizing particles, i.e. their energy is deposited in a target 
material in a two-stage process. In a first step, the neutrons interact with the 
nuclei of the target material and secondary particles are generated. In a second 
step, these secondary particles ionize the target material as they transfer their 
energy to the material. In tissue, the predominant neutron interaction is elastic 
scattering of hydrogen nuclei. At high neutron energies (above lOMe V), 
inelastic and non-elastic scattering reactions gain significance. In fast neutron 
therapy, the secondary charged particle spectrum in tissue consists of protons, 
alpha particles and heavy nuclear particles. These secondary charged particles 
have a high linear energy transfer (LET) value relative to that of electrons (ICRU 
36, 1983). The LET or stopping power is defined as 
LET =dE/dl 
where dE is the mean energy lost by a charged particle in collision along an 
element dl of its trajectory (Hall, 1988). The LET of secondary charged particles 
increases with increasing particle charge and decreasing speed. The dependence 
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of LET on particle type and energy is shown in figure 1.1. Due to the high LET 
of the secondmy charged particles generated, neutrons are generally referred to as 
high LET radiation. 
400 
200 
0.05 0.1 Q.2 0.5 2 5 10 
Instantaneous en£rgy (Me V ) 
Figure 1. 1: LET of various secondary particles as afunction of energy (Bewley, 1989) 
The relative biological effectiveness (RBE) of a neutron beam is dermed as the 
ratio of the dose of a reference photon beam to the dose of neutrons required to 
achieve an equal biological effect. The RBE is a function of the LET. What has 
been observed is that for a variety of mammalian cells, the RBE first rises to a 
maximum at about 100 ke V per micron and then falls as the LET increases 
(Bewley, 1989). The peak in the curve of LET versus RBE corresponds to the 
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optimal level of LET required for cell killing. After this point, a further increase 
in LET results in a decrease in RBE, as the additional energy deposited no longer 
contributes to cell killing because of the overkill effect. After this point, 
additional deposited energy is wasted (Hall, 1988). Figure 1.2 illustrates 




Figure 1.2: Variation in RBEwith LET (Modifiedfrom Bewley, 1989) 
Earnest Lawrence, the inventor of the ftrst cyclotron introduced neutron therapy 
in 1938 in the USA, six years after the discovery of neutron. The radiobiological 
information available at that time was inadequate and provided no deftnite 
rationale for using neutrons in prefc;rence to x-rays. The observed late effects 
were greater with neutrons than with x-rays and many patients suffered severe 
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late reactions (Stone, 1948). Consequently, the use of fast neutrons ill 
radiotherapy was abandoned for nearly 30 years (Raju, 1996). 
The rationale for re-introducing neutron therapy at the Medical Research Council 
in England can be summarized as follows: 
• The oxygen enhancement ratio (OER) is defined as the ratio of the dose 
required to obtain a radiobiological effect when the irradiation is performed 
under hypoxic versus oxygenated conditions. The value of OER for x-rays is 
about 3 and this value is reduced to 1.6 for neutrons. This implies that hypoxic 
cells are less effectively protected when treated with neutrons than with photons. 
Large tumours often contain a significant fraction of hypoxic cells and should 
respond favourably to neutron irradiation (Wambersie, 1992) . 
• The radiation sensitivity changes with phases of the cell cycle. With neutrons, 
there is less variation in the radiosensitivity between the cell phases. In tumours 
that are slow growing, the cells spend a longer time in the resting phase of the 
cell cycle, where they are relatively insensitive to photon radiation. These 
tumours are relatively resistant to conventional photon radiation but are less 
resistant to neutron irradiation, which therefore in principle has a better chance of 
effecting a cure (Raju, 1996). 
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Investigations by radio biologists provided clues regarding the types of tumours 
that are suitable for treatment with fast neutrons. They fOWld a wide range of 
neutron RBE values for tumours that exceed the range for normal tissue 
(Wambersie, 1992). Examples of tumours that are effectively treated with 
neutrons include salivary gland tumours, advanced breast tumours, head and neck 
tumours and certain tumours of other soft tissues. The types of tumours 
mentioned above and others are associated with 10 - 15% of radiotherapy 
patients (Wambersie, 1992). Therefore, it is important to properly select those 
patients for neutron therapy that are expected to benefit from it. 
1.3.2 The neutron therapy facilities 
Few fast neutron therapy facilities are currently in operation worldwide. In fast 
neutron facilities, neutrons are produced by protons or deuterons of energies 
above 30 MeV (Wambersie et al., 1999). The depth dose distribution of these 
beams is comparable to those achieved by 6 - 8 MV x-ray beams generated by 
linear accelerators. Isocentric gantries and multi-leaf collimators are installed at 
some facilities. The fast neutron therapy facilities that are currently in operation 
are listed in table 1.1. More than 25000 patients have been treated with neutrons 
worldwide to date (Jones, 1999). 
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..... ountrv Place Reaction Comments 
Belgium Louvain-Ia-Neuve 0(65) + Be Vertical beamline muItileaf collimator 
China Beijing 0(35) + Be Horizontal beam line. inserts 
United States Seattle 0(50) + Be Isocentric gantry multileaf collimator 
United States Batavia IL 0(66) + Be Horizontal beam line inserts 
United States Detroit d(50) + Be Isocentric. multo-rod collimator 
France Orleans 10(34) + Be Vertical beamline Inserts 
South Africa Faure 10(66) + Be Isocentric gantry muItileaf collimator 
South Korea Seoul 1 p(50) + Be Isocentric. variable jaws 
Table 1. 1: Currently operational fast neutron therapy facilities (Modifledfrom 
Wambersie et al., 1999). 
The National Accelerator Centre, at Faure in South Africa is the only neutron 
therapy facility in the southern hemisphere (Jones et al., 1995). Treatment of 
cancer patients at NAC began in 1989 on the p(66)/Be neutron therapy unit. A 
total of 1112 patients have been treated since then (Jones, 1999). Some of the 
tumours that are treated at NAC are head and neck tumours, salivary gland 
carcinoma, breast tumours, soft tissue sarcomas, uterine sarcomas, paranasal 
sinuses tumours and mesotheliomas (Stannard, 1998). 
The NAC facility is equipped with a separated sector cyclotron that can 
accelerate protons up to an energy of 200 MeV. This facility was planned 
specifically to provide research opportunities in natural sciences for users from 
allover the country and other parts of the world, to supply high-energy particles 
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for radiation thempy, and to produce radioisotopes for medical usc. Figure 1.3 
illustrates the layout of NACs major facilities. 
Neutrons arc produced by bombardment of a 19.6-mrn tlnel; bel)'lIiuJl1 target 
\\i!h 66 MeV protoll s. The proton beam dissipates 40 MeV of energy in this 
mrget and the remainillg energy 15 lost In a copper b~cl;ing and ill the cooling 
Wai;.,r. An isocentric gantl)' is capable of rotating the beam by ± 18S degrees. A 
collimator wllh a cOll tilluously variable rectangular ~penure provides field sizes 




'~~::- ~ ;> .. '" ~ 
, 
Fit:1m: I. J . L([yom of NACfffl.:ifuy 
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Figllre I . 4: ~ NAC's IN! I/Iron (""ropy isoc<!ntrlc gamry 
A mulhbladc trimmer, whieh ~i[s tllI~ adjusunent of tile size and the shape of 
the neutron field to match the size and shape of the tumour, has been installed 
(Jones el (II .. 1997) A diagram of the gantry. I'ohlch shows all the components, is 
shown in figure 1 4. A detailed description of tbe NAC facility can be found 111 
JoncH'lol (\994). Jonc$(.'1 al ( 1995) and Jones eI 01. ( 1999). 
The penetrlltion of the NAC neutron beam in Tissue is similar to thot of 8-M \' .\-
rays generated by a [mear acctler-llor. lbe percentage depth dose curve of the 
NAC p(66)1Be neutron beam and 8 MV x-rays IS shown in figure 1.5. The 
neurron dose ra tes are in the range of0.30 - 0.45 Gy/min (Jones el al 1995) 
" 
" 
,},-------;.c-------t,.,.------7 •• c-------.t. • .------;.!,-------.;-
D . ........ t . ... .. 
Figure J J. Ct'nlrul a.TI$ percell/age tlt'plII Ilose of Q p(66)8e lIelllron and 8 MI' x-ray 
bt!DmJ (M(}{/'(ied/rom Jone3 .. 1 III. 1989). 
1 A Thermoilimincsceni do~imelers 
IA.! Principle of operaltOn 
Some' cryslallinc materials. \\ hen irrMiiatcd by ionising radiation. s laTe pan oflhe 
energy absorbed In the cry51al lanice. When Ihe crystal IS subsequently heated. 
pan of the stored energy IS released as visible light. The amount of light released 
IS proponional 10 the amount of IOniSing rndilltlon 'he detector hhS been exposed 
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\0 The h1;h t that 15 released call be collecttd aud measured by II phmomulupher 
tul>e The phenomenon of visible photons released b) thermal means 15 called 
Thennolurmnescencc nlermohuninescellce hils been obseTled for cenTuries when 
cen alll fluorides and limestone hrlve been heated (Cmllcron ('/ al.. 19(8). 
nIl' sImple model or therrnoluminesccnce is illus tl llted in figure 1.6. In II pure 
cr)sTalime substnnce m room temp·crntule. the conduction band is completel} 
empty and all electrons res Ide m the valence band The valence band and the 
conduction band nre sepllmlcd b) 0 forbidden gill) The presence of Impuri ties III 
the ef)'slal 111 11) creatc energy tmp~ in the forbIdden gap, which lIIay provide 
Illclastllble ShUcS. When thc cr)swl IS imldllllcd. sOme of thc e lec!Tolls reccIVc 
suffiClenl energy to mOle to the conduction band lelllllllg II hole 111 [he valence 
bund The elecTrons lind holes lire free 10 lIlove in the cr)'st31 until Ihey recombine 
or [)c(:ome tmpped ulthe melllslllble SllItes. If the cl)slal IS heated. the electrons 
can acqulrt suffiCIent Ihemull eneTg) 10 escape the ITaII. and 1Il0l'l' to the 
conduction blind from \\llCrt Ihl!) Ina} filII 10 the \'lIlellCe b.1lld Tins tranSI tion 
lila) result 111 the ellllSSlOn of hght A plOi of the lIght output agamsttempermure 
IS o:all«l 1010\\ cur..-e (Khan, 199.1) FIgure 1.7 show~ a gTllph of The tempera ture 
lind the thcrmolulIllnescence (TL) OI.lIptU \'ersus lime 
J7 
al Irradla!lon b) Heal ing 
FiX"'" /1'1, Imlli/lI/lOtI (ll/d IW(ulIIg ~U/gl.'s uf II Ih.'rmolllmlfN!.SC""Ce prr:x:':5J (Khan, 
1'1';4), 
,/ Peak 5 
''''' 
~ 




F'g",e I 7: A TLJ). 700 glo .. c"" ... sJ,o"mg II>.! ~'(I'imiOtI 11/ l.:mpeTOlllr., (llId TL OlllfJlII 
.. IIh I'm;! 
A rcal phosphor normally consists of more than onc tfllppmg cenrre. ~ach 
trappmg centre caused by a l)8.nlcular latllcc dcfect. Each tTllllping le\'el gJxes 
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rise to all aSSOCiated glol' pea).. The area and helg.hl of cach glow peak dqJelld~ 
OIl Ihe number of associated cli.'1:trOIiS Imps prC.~IH, II h lC"h 111 tunl dell~' lId 0 11 the 
Jlumber of hlllie\' dcfl'1:ts. The laclors Ihat may nficcl the shape of the glow curve 
wcludc the follo\\"lI1g Ihc hC:llilig rate. size_ shape aud thennal conductivi ty of 
the sampic, Ihe recording IIlstnunelll used, Ihe radiation Iype and annc1Iling 
pl'Ocedul"c «(1I11II'rOn, 1968. i\kl-..i nlny 1981 ). 
1.-1.2 A!.I'-ilil tages aull lIisad\'illllages ofTL I) 
The advanlages lind dlsadl~ullages o f TLD have been discussed b) Kron (1999). 
mid can be $unln HlJ'll~'d 3S follow~; 
The advanlages are as follo\\s 
• TLD has a hnc:aT dOM: responsc over a II ide dose range 
• Thc efTeclI\"C alOmic number of TI D is 31lprOxllllotdy equal to thai of lissuc. 
1\]lIch IS imponallt for pholOfl dosllllelry \\ here the absOfbed dose is a 
functlon of the etTe<:hle atomiC number of the rnateri:Jl 
• ,\$ intcgnuing dOSimeters, they cou rnea:.urc doses OI1:r a long period 01 
lime 
• Rcusablt·. after 3ppl~ ing appropriate annealing procedures to release the 
SIOn.'tI encrg) 
" 
• The fact that no au.'tihary c:quipmenl5 ar~ n~"e(kd dunng irradiation enables 
lLD to be used as in-vIvo doslnlctCf'j and in medical physics, personnel 
dosnnetcrs, and as area monitors 111 h~alth phYSIcs 
• TIlc glo\\cum:s prOVIde the means of ~:<tracting additional informaTion from 
l LD readings as the ratio of the dilTereOl peak intensities arc relmed to LET. 
The disadvantages are as fo)[ows : 
• There are no lasting records except for II glowcurve and int~gm[ed output. 
• They are sensitive to e.~poSllre by ultraviolet lighT and therefore must be kept 
ill a dar$.: environment 
• Expensive readom eqUIpment IS re<juired to e\o·aluat~ the detectors. 
• TLDs require calibraTions because they are not absolu te dosimeters. 
I A.J ' \ ]lpl icll t ion ofTLO 
Different types of TLDs can be used for dilTe-rent applications in health and 
meaical physIcs. For environmental monitoring, TLDs life: e:mploye:d for the 
measurements of radiauon exposure from cosmic mdJalion e\posure in high 
alutude aircraft (Noll el 01 .. 1999), terrestrial radiallon III 5011 and rocJ. s, and 
IICcldental release of man-made radioactivity (McKinley, 198 1). The system is 
also employed 111 atomic energy cenlfcs and lSOIOpe laboratories for I~rsollllcl 
and are3 monitoring (McKm ley. 198 J). 
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The wide applications in medical physics include diagnostic and therapeutic 
purposes. In diagnostic radiology, TLDs are employed to investigate the radiation 
exposure in computer tomographic scans (Smith et ai., 1998), mammography, 
and x-ray examinations. In radiotherapy, they are employed for determining the 
dose distribution in phantom and as in-vivo dosimeters (K.ron, 1999). 
1.5 In-vivo TLD in neutron therapy 
The most commonly used TLD phosphors in radiotherapy are lithium fluoride 
(LiF) and calcium fluoride (CaF2)' LiF TLDs are available in many fonns, like 
microrods, granules, pellets, and discs. They are available in three different 
lithium isotope ratios: TLD-lOO which contains natural lithium (7.5% 6Li, 92.5% 
7Li), TLD-600 which contains 6Li only and TLD-700 which contains 7Li only. 
6Li has a high thennal neutron capture cross-section. TLD-100 and TLD-600 are 
therefore sensitive to thennal neutrons and are both used in personnel neutron 
dosimetry at reactor and accelerator facilities. For fast neutron in-vivo dosimetry 
the TLDs should be insensitive to thermal neutrons as their contribution to the 
dose is insignificant, hence TLD-700 is suitable for in-vivo neutron dosimetry. 
Both TLD-300 and TLD-700 have been investigated for use as in-vivo 
dosimeters in fast neutron therapy (Loncol et ai., 1996, Hocini et ai., 1988, 
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Angelone et al., 1998). TLD-300 is perhaps more widely used than TLD-700 for 
neutron dosimetry and they are the recommended TLDs for high LET dosimetry 
(Hoffmann, 1996). This recommendation is based on the fact that the response of 
the high temperature peak of TLD-300 is constant over a wide LET range. The 
response of the most other TLD peaks decrease with LET. This fact complicates 
in-vivo dosimetry if the chips are exposed to a beam that differs in LET from the 
calibration beam. Hoffman et al., 1983 have measured the response of both high 
and low temperature peaks in TLD-300 and TLD-700 versus the dose mean 
lineal energy, Yo (ICRU 36, 1983) This parameter is related to the average LET 
of the secondary particle spectrum of the beam. Measurements of Yo in a 
p( 66)/Be neutron beam show that Yo varies with field size and water depth in the 
region between 70 - 75 keY/micron (Binns et al., 1988). An analysis of 
Hoffman's et al. (1983) fmdings reveal, however, that in this Yo region both 
main dosimetry peaks, i.e. the high temperature peak in TLD-300 and the low 
temperature peak of TLD-700, exhibit a decrease in sensitivity with LET. It can 
be argued that in the aforementioned region the response of the low temperature 
peak in TLD-700 varies less with LET than the high temperature peak of TLD-
300. This is corroborated by Loncol et al. (1996) who observed that in a p(66)/Be 
beam, the low temperature peak of TLD-700 was the most independent one in 
terms of beam quality if compared with the TLD-300 peak. 
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A disadvantage of TLD-700 is the observed supralinearity with dose of its high 
temperature peak 6 (Rassow et al., 1988). The peak 615 ratio of TLD-700 is 
hence a function of absorbed dose and this dependency has to be corrected for. 
This can be achieved by mapping the supralinearity of the high temperature peak 
in the beam of interest. The high temperature ratio of TLD-700 shows a more 
pronounced dependence on LET than that of TLD-300 (Hoffmann et al., 1983), 
which is advantageous for high temperature ratio studies. We chose TLD-700 for 
our studies but this work could also have been performed with TLD-300. 
Blum et al. (1976) report the use of calcium sulphate (CaS04: Tm) TLD powder 
for the dosimetry of patients treated with a d(14)lBe neutron beam at Medical 
Research Council cyclotron at Hammersmith Hospital. Entrance and exit doses 
were measured on 50 patients treated mostly for head and neck diseases. At the 
entrance and exit side, the TLD measurements yielded a mean dose of 1.01 
±O.088 and 0.86 ± 0.17 respectively if compared to the treatment plan dose. An 
error analysis of the procedure yielded an expected random error of 8 % in the 
dose determination, which is in agreement with the observed standard deviation 
of entrance side measurement. The exit dose determination is complicated by 
transmission of neutrons through the patient and the unknown changes in the 
energy spectrum at depth. Numerous other authors have investigated and 
characterised the behaviour of TLDs in neutron beams (Loncol et al., 1996, 
Angelone et al., 1998, Rassow et al., 1988). However, to the best of our 
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knowledge Blum's results constitute the only published TLD neutron in-vivo 
measurements thus far. 
1.6 Aims of the thesis 
In this project, we intend to measure entrance and exit doses with TLD-700 for 
patients undergoing neutron therapy at the NAC. The entrance dose will be 
measured on the patient's skin surface on the central axis of the beam and the 
measured dose will be compared to the treatment plan dose. At the exit side of 
the beam, the exit dose will be measured on the skin surface on the central exit of 
the beam exit. The measured exit dose will be compared to the dose according to 
the treatment plan. 
The peak 6/5 ratio will also be investigated in our beam. The peak 6/5 ratio is the 
ratio of the thermoluminescence response of peak 5 to that of peak 6. It has been 
investigated by others and has been found to vary with LET. We will investigate 
the peak 6/5 ratio behaviour in the field and out of the field of the neutron beam 
with the aim of extracting further potential information. Variation in peak 6/5 
ratio will be compared with variations in beam quality. 
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Chapter 2: Experimental Methods 
2.1 Introduction 
In-vivo dosimetry needs to be perfonned with sufficient accuracy and precision 
in order to be useful. Only errors that are larger than the accuracy of the 
dosimetry system can be detected. In modern radiotherapy departments, that 
employ comprehensive quality assurance programs, an error in the dose delivery 
larger than 50/0 can still be expected in up to 1 % of all treatments (Essers et ai., 
1999). The accuracy of an in-vivo dosimetry system needs to be less than 5% to 
detect these errors. Carefully calibrated thennoluminescent detector systems can 
have accuracies of 2 - 5 % and are hence suitably accurate for in-vivo dosimetry 
(Essers et ai., 1999, KrOll, 1999). 
In an effort to achieve high accuracy and precision, TLD chips were sorted 
according to their reproducible responses. Chip-specific calibration factors were 
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detennined and used throughout this project. Furthennore, factors that influence 
the chip sensitivity were carefully investigated and, where necessary, correction 
factors were detennined and applied. In-phantom depth dose and cross-plane 
measurements were perfonned and compared with ionisation chamber 
measurements. 
All of the above procedures were aimed at improving the accuracy and precision 
of the TLD system and to demonstrate its feasibility for in-vivo neutron 
dosimetry. In this chapter the experimental procedures employed are detailed and 
the results of in-phantom measurements are presented. 
2.2 TLD readout 
The reader used for all measurements was a Solaro dual channel TLD processor 
that contains two readout channels and a drawer mechanism for loading chips. 
The Solaro is a computer- controlled system consisting of a reader, visual display 
unit and a keyboard. Round TLD-700 chips of LiF: Mg, Ti (ZefI = 8.2, P = 2.6 
glcm3) (McKinley, 1981) with a diameter of 4.5 mm and thickness of 0.9 mm 
were used. Before irradiation, the chips were annealed in a computer-controlled 
oven. The chips were heated to 400°C and held at this temperature for one hour. 
This was followed by twenty hours of baking at 80°C before the chips were 
cooled down to room temperature. 
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The TLD chips were read 24 hours after irradiation in a nitrogen atmosphere at a 
heating rate of 10 °C/s. The heating cycle used was as follows: 15 seconds 
preheating at 160°C, followed by 35 seconds read time, i.e. 20 seconds at 160-
350°C and constant temperature at 350 °c for 15 seconds. This is followed by 10 
seconds annealing at 350°C. The glow-curve data were stored in a computer for 
subsequent analysis. The thermoluminescence signal versus temperature/time or 
glow-curves were used to integrate the peaks, peak 5 (200 - 300 °C) and peak 6 
(300 - 350°C). Peak 5 is the dominant glow curve peak and therefore was taken 
as the main dosimetry peak to determine the absorbed dose. 
2.3 TLD chip selection and calibration 
This section explains the procedures used to select "good" chip with reproducible 
response from the available ones. Since chip-specific calibration factors are later 
assigned to all selected chips, the chip's signal reproducibility was chosen as a 
measure of the chip goodness. This procedure is based on peak 5 only since it is 
the main dosimetry peak in TLD-700. 200 chips were irradiated with a dose of 
one gray in the neutron beam. The mean reading over all chips was calculated 
and the deviation from this mean was calculated for each individual chip. This 
procedure was repeated three times. The standard deviation of the three 
deviations from the mean was then computed and this figure was subsequently 
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used as the measure of the reproducibility of the chip. Although a single chip 
might show a large deviation from the mean value, it might be a "good" chip 
because of the reproducibility of its signal. All chips for which the standard 
deviation (10') of the deviations from the mean was better than 3.5% were 
selected for later use. Exactly 110 chips satisfied this criterion. 
For each of the selected chips an individual calibration factor F was calculated as 
follows; 
F = D [GY] 
(rl + r 2 + r3 ) I 3 TL .signal 
where D is the absorbed dose in Gy, i.e. 1 Gy, rj, r2 and r3 are the chip signals 
due to the first, second and third irradiation. 
The TLD chips used in the project were in constant use and the TLD radiation 
history can change the TLD response. Therefore, all chips were re-calibrated 
after 12 months. We found that the overall sensitivity of the chips had dropped 
by 1 to 2 % over this period in which the chips received an approximate 
accumulative dose of 30 Gy. The observed decrease of sensitivity with 
continuous use of the chips is in qualitative agreement with studies done by 
others (Cameron, 1968). The re-calibration of the chips is therefore 
recommended every twelve months. 
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2.4 Dose linearity 
The chip-specific calibration factors were detennined at an absorbed dose level 
of 1 Gy in the p( 66)lBe neutron beam. It can not be assumed that these 
calibration factors are valid at other dose levels. The dependence of the TLD-700 
peak sensitivities on absorbed dose was reported previously (Meissner et al., 
1988, Pradhan et al., 1985, Rassow et al., 1988, Waligorski et al., 1980). 
To characterise the dose response of TLD-700 in our neutron beam, TLD chips 
were irradiated with absorbed doses ranging from 0.01 to 3 Gy. For each run 10 
chips were placed in a nylon 6 phantom and were irradiated at a water equivalent 
depth of2 cm (nylon depth of 1.6 cm). The phantom was made up of nylon slabs 
that were 10 cm x 10 cm in size (p = 1.2 glcm3) and 0.8 cm thick (1 cm water 
equivalent depth). The slabs, which held the TLD chips, had I-mm deep holes for 
the TLD chips. After read out the peak 5 reading was converted into response 
using the individual calibration factors detennined earlier. The response of the 
main dosimetry peak, peak 5, as a function of absorbed dose, is shown in 
figure 2.1. 
The observed saturation effect of peak 5 can not be corroborated by other 
published fmdings. Several dose linearity studies in the d(14)lBe neutron beam at 
Essen confmn the linear response of peak 5 up to the dose of 100 Gy (Meissner 
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et al.,1988, Pradhan et al., 1985, Rassow et ai, 1988). Irradiation in a cobalt-60 
beam showed a slight supralinear response of peak 5 at an absorbed dose of 100 
Gy (Pradhan et al., 1985,Waligorski et al., 1980). Only at an absorbed cobalt-60 
dose of 1000 Gy was saturation observed (Waligorski et al., 1980). These 
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Figure 2. 1: Response as afunction of neutron dose of the main dosimetric peak 5. Each 
data point represents the mean of 10 TW chips. The error bars refer to the error of the 
mean (18). 
It should be remembered that the saturation of the recorded thermoluminescence 
signal could be due to a reduced thermoluminescent chip output or a saturation of 
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the light collection apparatus. This was investigated by comparing TLD readings 
of our reader with those obtained from a reader belonging to a neighbouring 
hospital. TLD chips were irradiated with cobalt-60 doses ranging from 0.1 Gy to 
15 Gy. Chips were read in our Solaro TLD reader. The cobalt-60 irradiations 
were repeated and the chips were read using the Toledo TLD reader at the Groote 
Schuur Hospital (GSH) in Cape Town. Figure 2.2 shows the results of both 
readings. The Solaro TLD reader results exhibit saturation whereas the GSH 
Toledo results are linear up to 15 Gy. However, since the same 
thermoluminescent chips and Solaro reader were used for all subsequent 
measurements, a correction of the observed saturation effect is possible. 
3.0.E+07,..-----------------------., 
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Figure 2. 2: Dose response in cobalt beam/or a Solaro and a Toledo reader. 
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To relate the thermo luminescent response to the absorbed neutron dose for all 
subsequent measurements a curve fitting routine was used to detennine the 
absorbed neutron dose as a function of the thermo luminescent response. Figure 
2.3 (equivalent to figure 2.1 but with reversed axis) shows the absorbed dose as a 
function of response and illustrates the applied curve fitting routine. The 
following 7th order polynomial equation was derived: 
Absorbed neutron dose [Gy] = a+br+cr2 +drl +er4 + jrS + gr6 +hr7 
where a = -0.01178, b = 1.357024, c = -5.72469, d = 24.18364, e = -54.3928, 
f = 64.16435, g = -36.4562, h = 7.878924 and r is a thermoluminescence 
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Figure 2.3: Peak 5 dose as afunction of response 
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2.5 Depth dose curves 
A neutron beam that is generated by bombarding a semi-thick beryllium target 
with 66 Me V protons has a wide energy spectrum that ranges from thermal to 66 
MeV neutrons (Jones et al., 1995, Awschalom et al., 1983). When this neutron 
spectrum penetrates into tissue, the lower energy neutrons are preferentially 
absorbed, which leads to beam hardening at depth (Slabbert et al., 1989, Homsey 
et al., 1988). At the NAC p(66)/Be facility a 2.5 cm polystyrene filter is used to 
harden the beam and therefore to reduce the beam hardening effect in the patient 
(Jones et al., 1994). However, a remaining beam hardening effect has been 
observed in the filtered beam. Using micro dosimetric measurements, a 6 % 
reduction in the beam's potency has been detected with depth between 2.5 cm 
and 20 cm (Slabbert et al., 1989) and between 5 cm and 25 cm (Binns et al., 
1992). Changes in the neutron energy spectrum with depth may be of concern for 
thermoluminescent dosimetry since the sensitivity of TLD-700 is a function of 
the neutron energy spectrum (Hocini et al., 1988). The aim of the following 
experiment was to test the magnitude of this effect on the TLD sensitivity and to 
test whether TLD chips can be used to verify the absorbed dose at different 
depths in the phantom. 
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In the experiment the detectors were divided into groups of 8 and stacked in a 
nylon phantom at different depths ranging from 0 to 20 cm. A diagram of the 
experimental set up is shown in figure 2.4. For a 5.5 cm x 5.5 cm field, a dose of 
1 Gy at 2-cm water equivalent depth was given to the stack. The procedure was 
repeated at different fields sizes, i.e., 8 cm x 8 cm and 10 cm x 10 cm and 15 cm 
x 15 cm. For the two smaller field sizes, the phantom size was 10 cm x 10 cm. 
For the larger field sizes a 20 cm x 20 cm phantom was used. The data obtained 
were corrected for dose nonlinearly in peak 5 using the equation obtained earlier. 
Beam direction 
- - - I~ +----- - ~ 
0.8 cm nylon 6 




/ .... .... 
TLDs 
Plain nylon 6 slab 
/' 
.....;:: -s;: 
Figure 2. 4: Diagram of the phantom set up. All slabs are 0.8 em thick. Plain slabs are 
used to adjust the space between the TLD bearing slabs. 
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A plot of the absorbed dose measured versus depth for different field sizes is 
shown in figure 2.5 to figure 2.8. The depth dose distributions obtained with TLD 
chips were compared with relative ionisation chamber measurements. Numerical 
results are listed in table 2.1. The TLD data in figure 2.5 to figure 2.8 represent 
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Figure 2. 5: Depth dose curve for a 5.5 x 5.5 em field 
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Figure 2.8: Depth dose curvefora 15 cmx 15 cmjield 
Depth rem1 5.5 x 5.5 SxS 10 x 10 15 x 15 
1 0.913 ± 0.021 0.971 ± .0017 0.993 ± 0.020 1.035 ± 0.019 
2 1.000 ± 0.017 1.018 ± 0.018 1.009 ± 0.019 1.077 ± 0.018 
5 1.047 ± 0.023 0.989 ± 0.021 1.031 ± 0.022 1.026 ± 0.017 
10 1.015 ± 0.015 1.056 ± 0.017 0.987 ± 0.043 1.029 ± 0.013 
20 1.127 ± 0.017 1.043 ± 0.019 0.979 ± 0.034 0.998 ± 0.018 
Table 2. 1: The TLD sensitivity in the neutron beam (i.e. TLD dose I ionisation chamber 
dose) for differentjield sizes and depths. 
The TLD response in two parallel opposed fields has been measured. The 
experimental set-up is similar to the 10 em x 10 em depth dose measurements but 
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the beam angles were 90 ° and 270 o. Using two 10 x 10 cm2 fields at 150 cm 
SAD, a dose of one gray was given at each angle. The TLD results were 
compared to ionisation chamber data that was calculated by adding two opposing 
field depth dose ionisation measurements. Figure 2.9 shows the results. 
Qualitatively, an increased thermoluminescence sensitivity at depth may be 
-
expected. This is due to two effects. Firstly, YD slightly decreases at depth 
-
(Binns, 1993) and the TLD-700 peak 5 sensitivity increases with decreasing YD 
(Hoffmann et al., 1983). Secondly, the gamma component increases with depth 
(Jones et al.,1995), which again results in an increased thermoluminescence 
sensitivity to the total dose. With the exception of the smallest field, our results 
however, show that these effects are negligible in magnitude. Quantitative 
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Figure 2. 9: Depth dose eurve for two 10 em x 10 em parallel opposed fields 
Microdosimetric measurements show that YD decreases only slightly with depth 
from 83.5 - 79.4 keV/J.1m between 2.5 and 20 cm (Binns, 1993). The gamma 
component is almost constant with depth in a p(66)/Be neutron beam. It increases 
from 4 to 6 % from 2 cm to 20 cm depth (Jones et al., 1995). Since the 
thermoluminescent sensitivity is roughly twice for cobalt-60 than for p(66)/Be 
neutron beam (Hocini et al., 1988), an increase of thermoluminescent sensitivity 
of 2 % can be expected. Both above effects are small in magnitude, which is in 
agreement with our fmdings. We conclude that the TLD-700 peak 5 can be used 
to determine the absorbed dose at depth in a p( 66)/Be neutron beam. 
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2.6 Beam profiles 
Two processes can affect the overall quality of the neutron therapy beam at the 
field edges. Firstly, the primary beam softens as a result of beam scattering and 
secondly, the photon component increases sharply (Binns et al., 1993, Jones et 
al., 1992). Both effects can influence the thennoluminescence sensitivity in the 
penwnbra region. This experiment was perfonned to investigate whether TLD-
700 chips can be used to measure absorbed doses in the penwnbra region of the 
field. 
In the following experiment, measurements were perfonned in the central axis of 
the beam and in the penwnbra region at a depth of 2 cm. Chips were irradiated in 
a 5.5 cm x 5.5 cm field and at distance of 1 - 5 cm off-centre. The dose measured 
in peak 5 is plotted against off-axis distance. The beam profile is shown in 
figure 2.10 and nwnerical results are listed in table 2.2. 
Binns, (1993) and Jones et al., (1992) perfonned measurements in the penwnbra 
region at the NAC neutron beam facility. Marked changes were observed in the 
penwnbra region where the photon component was found to increase 
substantially. The sharp increase in the gamma component should lead to an 
increased TLD sensitivity in the penwnbra region. Our results however, showed 
a general decrease of TLD sensitivity in this region (Table 2.2). This may be due 
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to a softening of the neutron component in the penumbra region. A softening of 
-
the neutron component leads to an increase YD value (Pihet et al., 1988), and the 
-
TLD-700 peak 5 sensitivity decreases with increasing YD value (Hoffman et al., 
1983). A quantitative investigation of this effect can be performed with 















-- Ion chani:>er 
• PeakS 
-4 -2 o 2 
Distance from central axis [cm] 















TLD I Ionisation chamber 
0.741 ± 0.026 
0.790 ± 0.031 
0.754 ± 0.042 
1.002 ± 0.043 
1.005 ± 0.044 
0.950 ± 0.040 
0.985 ± 0.042 
1.031 ± 0.045 
0.679 ± 0.026 
0.946 ± 0.037 
Table 2. 2: The ratio of TLD dose (Gy) and ionisation chamber dose (Gy) with the 
co"esponding distance from central axis. Measurements were taken in a 5.5 cm2 field at 
a water equivalent depth of 2 cm. 
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Chapter 3: In-vivo dosimetry 
3.1 Introduction 
In-vivo dosimetry can be subdivided into entrance, exit and organ dose 
measurements (ICRU 24, 1976). Each category has a distinctly different purpose. 
The measurement of entrance dose is perhaps the most common case of in-vivo 
dosimetry. Here the dose that the patient receives at a point on the field entrance 
side of the body is determined and compared to that calculated in the treatment 
plan. Errors in patient positioning, patient set-up and machine parameters can in 
principle be detected. 
In-vivo dosimetry of exit doses is complicated by the fact that the calculations of 
the exit dose need to account for the body's inhomogeneities. Unless this is 
properly done discrepancies between the measured and calculated exit dose can 
be expected. Hence, exit dose in-vivo dosimetry can be used to gain information 
43 
about the validity of the treatment plan calculations rather than to detect set up 
errors. 
Organ dose measurements are employed to measure the dose to organs that are 
accessible. This can be done in the radiation field or outside the field boundaries. 
In the latter case, complications arise in neutron therapy due to the qualitative 
changes of the neutron beam in the penumbra region. 
In the previous chapter we have established the feasibility of using TLD for in-
vivo dosimetry in the radiation field. Actual in-vivo measurements were 
performed in 9 fields (7 patients) where entrance and exit doses were measured 
in the direct radiation fields. 
The planning of the treatments was performed on the Theraplan computerised 
planning system at Groote Schuur Hospital. All treatment planning and patient 
set-ups were performed by the radiographers. Most of the patients that 
participated in the study were treated for head and neck diseases. Field sizes 
varied from 6.7 to 10.7 equivalent square centimetres with and without wedge 
filters. All fields were adjusted in shape using a multi-blade trimmer (Jones et al., 
1997). The treatment plan doses were calculated from the treatment plans and 
were in the range of 0.46 Gy to 1.3 Gy. ParatIm wax lined with lead was used as 
a bolus material in most treatments. Wax is less dense than water (0.93 g/cm3), 
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has higher hydrogen content (14.6 %), and is therefore similar to water in tenns 
of neutron attenuation (Hess et al., 1991). The bolus is placed directly on the skin 
surface to smooth out irregular contours of the patient to present a flat surface 
normal to the beam. The lead lining is used to recover the skin dose that is lost 
due to the presence of tissue compensator (Hess et al., 1991, Jones et al., 1988). 
In situations where the wax was used, the detectors were taped to the surface of 
the wax on the central axis of the beam. Table 3.1 details the patient set up during 
treatment. 
Field Field size Site Wax Lead lining # of session! 
no. (em xcm), total 
WOOle 
lA 8x 17 Head & neck Yes Yes 7112 
IB 8X 17 Head & neck Yes Yes 7/12 
2 7 x 12.5, W2 Lumbar spine No No 4/12 
3 5.5 x8.5, W2 Head & neck Yes Yes 5112 
4A 9X5.5, W2 Head & neck Yes Yes 9112 
4B 9 x6.5, W2 Head & neck Yes Yes 9/12 
5 7.5 x 9, W2 Head & neck Yes Yes, except over 11112 
scar 
6 7.5 x 9, W2 Head & neck Yes yes 9/12 
7 10 x 11, W3 Head & neck Yes Yes, except next to 7/12 
nose 
Table 3. 1: Details of patient set up during treatment. The W2 and W3 refer to the 
wedge number. The wedges W2 and W3 are 35 and 45 degree wedges respectively. The 
last column gives the number of the session when the in-vivo dosimetry was performed 
out of the total number of sessions. 
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3.2 Entrance dose measurements 
Discrepancies between the actual patient or machine set-ups and those used in the 
treatment plan will lead to a difference in measured and planned absorbed dose. 
For example, Leunens et al. (1990) detected errors in patient positions, patient set 
up, external patient contours and errors due to the repeated treatment 
interruptions by means of entrance in-vivo dosimetry. 
In-vivo entrance measurements were performed on the patient's skin surface or 
on the patient's mask surface. For entrance dose measurements we used a 2 mm 
thick A150 plastics (p = 1.12 glcm3) as a build up material to avoid the "peak 6/5 
ratio" in the glowcurve at the surface as it makes peak 5 read-out more difficult. 
Chapter 4 explains the high temperature ratio method in detail. 
The dose given to the patient according to the treatment plan is defined at a depth 
of 2 cm. Hence, a mechanism was needed to relate the dose at 2 cm to the dose 
measured at the patient surface under 2 mm A150 plastic build up. It is the aim of 
the following experiment to measure the dose at 2 mm depth relative to that at 2 
cm depth for different field sizes. At the surface of a nylon-6 phantom and at a 
depth of2 cm, measurements were performed for field sizes ranging from 5.5 cm 
x 5.5 cm to 29 cm x 29 cm. For these phantom measurements, the 'surface' TLDs 
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were covered with 2 rom A150 tissue equivalent plastic. Figure 3.1 shows a 
diagram of the experimental set up. 
Beam direction 
111 2 mm AI50 plastic 
~ }4 -- 2 em water equivalent nylon --~ --- TLDs 
10cm .. Plain nylon slab 
10 em 
Figure 3. 1: Diagram o/the experimental set up. 
A plot of square field size versus relative dose measured at 2 rom depth is shown 
in figure 3.2. An equation that allows calculation of the relative entrance dose as 
a function of equivalent square field was calculated from the data and was later 
used in the entrance dose calculation. The equation is as follows; 
Relative dose (EQS) = -O.Ol02EQS2 + O.5699EQS+ 53.55 , where EQS represent 
the equivalent square field. 
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Awschalom et 01. (1981) derived an expression for calculating the central axis 
depth dose in the build up region as a function of equivalent square field in the 
p(66)/Be beam at Fermilab. We use this expression to compute the relative 
entrance dose at a depth of 2 mm as a function of equivalent square field for 
comparison to our results. Figure 3.2 also shows the results obtained by 
computing Awschalom's expression. Awschalom's results are normalised to ours 
for the 10 cm x 10 cm field. Both sets of results are in qualitative agreement The 
effect of increased relative depth dose at 2 mm depth with increased field size is 
more pronounced in the Fermilab beam. The Fermilab neutron therapy beam is 
generated in a thicker beryllium target, i.e. 2.21 cm than the NAC beam and no 
polyethylene hardening filter is used in the Fermilab beam (Rosenberg et 01., 
1981). 
In-vivo measurements were performed on seven patients (9 fields). For each in-
vivo measurement six TLD chips were used. The mean value and standard 
deviation of the mean are quoted. Entrance dose measurements were performed 
at the skin surface or on top of the paraffin wax at the radiation field centre. The 
2 mm A150 build up slab was cut into size and shape so as to cover six TLD 
chips. We used the results from the previous experiment to compute the relative 
entrance dose for each radiation field, which was then used to calculate the dose 
at 2 cm (100% dose). The determined dose at 2 cm was compared with the 
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Figure 3.2: Entrance dose as ajunction offield size. The data represent the mean TLD 
reading over 5 TLD chips. Awschalom 's results are also plotted 
Within the stated experimental uncertainties, all but two in-vivo entrance doses 
are in agreement with the expected absorbed doses according to the treatment 
plan. Large errors « 5%) were not detected and with one exception all 
discrepancies were smaller than 3%. The two measurements performed on 
patient 4 show the two largest discrepancies. No reason is apparent for this. 
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Averaged over all 9 fields, the TLD measurements are 1.7 % higher than the 
expected treatment plan doses. 
Patient information Entrance dose 
Patient Field no. EQS Measurement 100% T. plan TLD/T.Plan 
[cm]2 [Gy] [Gy] [Gy] 
Patient 1 1 10.9 0.727::J: 0.003 1.242::J: 0.005 1.226 ::J: 0.025 1.013 ::J: 0.021 
2 10.9 0.730::J: 0.009 1.247::J: 0.016 1.226::J: 0.025 1.017::J: 0.024 
Patient 2 2 8.8 0.560::J: 0.007 0.978::J: 0.012 0.955::J: 0.019 1.024 ::J: 0.024 
Patient 3 2 6.7 0.681 ::J: 0.007 1.197::J: 0.012 1.189::J: 0.024 1.007 ::J: 0.022 
Patient 4 2 7.5 0.607::J: 0.004 1.060::J: 0.007 1.035::J: 0.021 1.024::J: 0.022 
1 6.8 0.716::J: 0.004 1.257::J: 0.008 1.218::J: 0.024 1.032 ::J: 0.022 
Patient 5 3 8.2 0.663::J: 0.007 1.152::J: 0.013 1.126::J: 0.023 1.023 ::J: 0.023 
Patient 6 3 8.2 0.648::J: 0.019 1.126 ::J: 0.033 1.126::J: 0.023 1.000 ::J: 0.036 
Patient 7 4 10.5 0.275::J: 0.012 0.471::J: 0.021 0.466::J: 0.009 1.012::J: 0.050 
Table 3. 2: Entrance dose measurements. EQS refers to the equivalent square field 
obtained from treatment charts. The surface dose was measured at the patient skin 
surface under 2-mm A150 plastic. The 100% dose at 2 cm was computedfrom the 
measured dose. T.Plan refers to the dose at 2 cm according to the treatment plan. A 2% 
uncertainty was assigned to the calculation of the treatment plan dose. The last column 
compares the determined dose at 2 cm to the dose according to the treatment plan. 
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3.3 Exit dose 
To verify the feasibility of using TLD for exit dose measurements, the following 
experiment was performed. The relative exit dose was measured with a parallel 
plate ionisation chamber and compared to TLD measurements. The phantom was 
made up of nylon 6 slabs with a total water equivalent thickness of 15.5 cm. The 
parallel plane ionisation chamber was positioned at a depth of 2 cm and the 
phantom was irradiated with a 0.5 Gy neutron dose. The parallel plate ionisation 
chamber was then positioned at the back surface of the phantom and again the 
phantom was irradiated with 0.5 Gy. In a third run, the TLDs were positioned at 
2 cm and at the exit side of the phantom. The phantom was again irradiated with 
0.5 Gy. The ratio of the dose measured at 2 cm to that at 15.5 cm was 0.55 ± 
0.005 for the parallel plate ionisation chamber and 0.55 ± 0.012 for TLDs. The 
results agree within the experimental uncertainties. 
Six of the nine fields that were subject to entrance in-vivo measurements were 
also used for simultaneous exit in-vivo dosimetry measurements. At the exit side 
of the patient the detectors were pasted on to the skin surface on the central axis 
of the beam exit. The measured exit dose was compared to the exit dose 
according to the treatment plan. 
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The exit dose is not routinely calculated in the treatment plan. To compare our 
exit dose measurements to the calculated exit dose the following procedure was 
employed. Each field of interest was separately calculated in the planning 
system. The isodose line at the field exit side was calculated and the exit dose 
was computed relative to the 100 % dose at 2 cm depth. 
The treatment plan assumes full backscatter at the exit side of the patient, which 
in reality is not there. In order to compare the measured dose and the dose 
according to the treatment plan, we need to subtract the backscatter component in 
the treatment plan dose. Awschalom et al. (1982) investigated the effect of 
missing backscatter on the dose distribution of a p(66)Be(49) neutron beam at the 
Fennilab neutron therapy facility. The expression derived by Awschalom et 
al.(1982) is D(t) = l_Ae- tfB , where D(t) is the normalized ionisation for 
backscattering thickness t, and A and B are a function of field size, A and B are 
0.0165 + 0.0030EQS and 2.55 + 0.070EQS respectively. Results indicate that the 
dose reduction at the exit surface of the phantom due to the missing back scatter 
can be as large as 4% to 10% depending on the equivalent square field size. Since 
the neutron therapy facility at NAC is similar to the Fennilab facility, the results 
obtained at Fennilab are used for the backscatter correction in the NAC beam. 
The backscatter component was computed for each equivalent square field and 
subtracted from the treatment plan dose. Table 3.3 summarises the results. 
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Discrepancies up to -7.3 % were detected. A systematic discrepancy of- 5.1 % is 
apparent. The treatment plan does not correct for any patient inhomogeneity and 
is based on the assumption that the whole patient is water. These inaccuracies 
seem to lead to a systematic overestimation of the patient exit dose. 
Patient infonnation Measured Treatment plan 
Patients Field EQS Thickness Exit dose 100% % exit BSF Exit dose 1LDff.PIan 
no. [cmxcm [cm] [Gy] [Gy] [%] [%] [Gy] 
Patient I I 10.9 17 0.582 :1::0.012 1.226:1:: 0.025 ~ -4.92 0.606:1:: 0.012 0.960:1:: 0.029 
2 10.9 17 0.564 :I:: 0.004 1.226:1:: 0.025 52 -4.92 0.606 :1::0.012 0.930:1:: 0.021 
Patient 2 2 8.8 32 0.161 :1::0.002 0.955:1:: 0.019 19 -4.29 0.174 :1::0.003 0.925:1:: 0.025 
Patient 3 2 6.7 17.5 0.470:1:: 0.009 1.189:1:: 0.024 44 -3.66 0.504 :I:: 0.010 0.933 :I:: 0.028 
Patient 4 2 7.5 15 0.432:1:: 0.013 1.035:1:: 0.021 45 -3.90 0.448:1:: 0.009 0.964 :I:: 0.037 
Patient 5 3 8.2 15 0.520:1:: 0.007 1.126 :I:: 0.023 50 -4.11 0.540 :I:: 0.011 0.964 :I:: 0.024 
Patient 6 4 10.5 20.2 0.167:1:: 0.005 0.466:1:: 0.009 39 -4.80 0.173 :I:: 0.003 0.965:1:: 0.034 
Table 3.3: Exit dose measurements. 'Measured' refers to the dose measured at the exit 
patient skin surface with TWs; 100 % is the dose at 2 em depth according to the 
treatment plan. '% exit • refers to the percentage exit dose according to the treatment 
plan. BSF is the backscatter factor for each EQS calculated using Awschalom's 
expression. The exit dose is the dose according to the treatment plan minus the 
backscatter component. The last column is the ratio of the measured exit dose to the 
back scatter component corrected treatment plan dose. 
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Chapter 4: Glow curve analysis 
4.1 Introduction 
The TLD-700 glow curve exhibits a dominant peak (5) at about 250°C and a 
second high temperature peak (6) at about 330 DC. Both have different absolute 
sensitivities and LET dependent sensitivities (Hoffmann et al., 1983). The peak 
615 ratio is therefore LET dependent and increases with increasing LET. 
While glow curve analysis has been used to investigate the gamma component in 
neutron therapy beams (Meissner et al., 1988), other authors have used the two-
peak or high temperature method to determine the average LET of mixed 
radiation fields in space and in high altitude aircrafts (e.g. Noll et al., 1996 and 
Vana et al., 1996). We have investigated the peak 615 ratio in our neutron therapy 
beam with the aim of extracting further useful information from the glow curve 
and to relate changes in peak 615 ratio to changes in LET. We will investigate the 
behaviour of the peak 615 ratio in our p( 66)IBe neutron therapy beam as a 
function of depth and off axis-distance. 
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4.2 Peak separation 
The Solaro TLD software that is used to analyse glow curves does not allow the 
automatic separate analysis of peak 5 and 6. The peak 5 and 6 counts are 
obtained by manually analysing the glow-curve. Three methods of glow peak 
separation were evaluated. Firstly, peak 5 and peak 6 were separated by dividing 
the thennoluminescent integration time into two regions. Counts integrated 
between 160°C and 300 °c are assigned to peak 5 while counts above 300°C are 
assigned to peak 6. This method is referred to as manual integration. Secondly, 
the peak height was chosen as a measure of peak intensity. Lastly, both peaks 
were fitted using a curve fitting routine and counts were integrated accordingly. 
Figure 4.1 illustrates the last method. All three methods were applied to 10 glow 
curves of chips that had been irradiated in the neutron beam at various depths. 
Table 4.1 gives the peak height ratio as determined by the first two methods 
relative to the curve fitting method. 
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Peak 6/5 Manual Peak height 
(curve fittimz) curve fittimz curve fittimz 
0.132 l.57 0.93 
0.129 1.56 0.96 
0.104 1.52 0.88 
0.093 1.51 0.81 
0.076 1.48 0.86 
0.075 l.55 0.87 
0.074 1.61 0.81 
0.079 1.58 0.82 
Table 4. 1: Column 1 is the peak 6/5 ratio as determined by the curve fitting method. 
Column 2 and 3 give the peak 6/5 ratio determined by the manual integration and peak 
height methods relative to the peak 6/5 ratio determined by the curve fitting method. 
The curve fitting procedure is very time consuming and the manual integration 
method was therefore used throughout the thesis. Since variation in peak 615 ratio 
rather than absolute peak 615 ratios were investigated, the error incurred by using 
manual integration was deemed acceptable. However, for future glow curve 
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Figure 4. 1: Peak 5 and 6 analysed by a fitting program. 










The supralinear dose response of TLD-700 peak 6 has been observed in cobalt-60 
beams but not in a d(14) + Be neutron beam (Pradhan et al., 1985, Rassow et al., 
1988). No linearity studies have been published for fast p(66)/Be neutron beams. 
Rassow et al. (1988) reported that the phenomenon of TLD peak dose 
supralinearity is a function of the beam's LET. Since the average LET of a 
p(66)/Be beams differs from that of a d(l4)/Be beam (Pihet et al., 1988), we 
investigated the peak 6 supralinearity in our beam. 
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All data is obtained from the experiment perfonned in section 2.4. The chip 
individual calibration factors determined in peak 5 were also used for peak 6. The 
dose response of peak 6 is shown in figure 4.2. The observed supralinearity 
makes the peak 6/5 ratio dose dependent. This effect needs to be corrected for 
before the peak 6/5 ratio dependency on LET can be investigated. In section 2.4, 
we have detailed the saturation correction of peak 5. The same fonnalism can be 
used to correct the supralinearity of peak 6. A curve fitting routine was applied to 
determine the absorbed dose as a function of thennoluminescent response. The 
following fourth order polynomial was derived and was later used to correct the 
dose non-linearity in subsequent measurements. 
Absorbed dose (Gy) = ar3 + br2 + cr + d, 
where a = 1.115, b = -2.6421, c = 3.9537, d = 0.0024 and r is a 
thennoluminescence response. 
The equation was derived by reversing the axes and expressing the absorbed dose 
as a function of response. Since both equations (for peak 5 and 6) correct the 
non-linear TLD response in tenns of given dose, the peak 6/5 ratio is unity by 
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Figure 4.2: Dose response o/peak 6 o/TLD-700. 
4.4 Peak 6/5 ratio versus depth measurements 
The neutron spectrum changes with depth due to beam hardening (Slabbert et ai., 
1989, Homsey et ai., 1988)). In chapter 2, the influence of this effect on the 
TLD sensitivity was investigated. In this chapter, we will investigate the 
influence of this effect on the peak 6/5 ratio. Results were obtained by analysing 
the peak 6/5 ratio of the TLD chips that were irradiated in the experiment 
described in section 2.4. Additional irradiations were done to investigate the peak 
6/5 ratio in the built up region of the beam. 
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The peak 6/5 ratio was obtained by dividing the dose in peak 6 to the dose in 
peak 5. The results for a 5.5 em x 5.5 em field to 15 em x 15 em are shown in 
figure 4.3 to figure 4.6. The peak 6/5 ratio measured in all curves is relatively 
high at the surface and is fairly constant for deeper depths. 
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Figure 4.3: Peak 615 rati%r a 5.5 x 5.5 cmfield 
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Figure 4. 4: Peak 615 ratio for a 8 em x 8 em field 
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Figure 4.5: Peak 615 ratiofor a 10emx 10 emfield 
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Figure 4. 6: Peak 6/5 ratio for a 15 em x 15 em field 
Investigations into the peak height ratio of TLD-700 dosimeters by Loncol et al. 
(1996) in a p( 65)lBe beam showed that there was little change in the ratio with 
depth under comparable irradiation conditions, i.e. open beam and at depths 
ranging from 2 to 15 cm. The fmdings are in agreement with ours. This indicates 
that peak 6/5 ratio is not sensitive to the beam quality changes observed in the 
NAC beam at depth by Slabbert et al. (1989) and Binns et al., 1992. However, 
the observed high peak 6/5 ratio at the surface prompted an investigation of the 
peak 6/5 ratio in the built up region. 
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A nylon phantom and sheets of 1 mm A150 build up were used in the 
experiment. In the fIrst set-up, 8 TLDs were placed at the surface of the phantom 
without build up and were irradiated. This procedure was then repeated in steps 
of 1 mm until a depth of 20 mm was attained, i.e. 1 mm of A150 build up was 
added each time. Each set up was irradiated with a dose of one gray defmed at 2 
cm depth. The results are shown in fIgure 4.7. The extrapolation chamber 
measurements were plotted for comparison (Jones et al., 1994). 
The neutron beam produces secondary charged particles that have different 
ranges in tissue and attain equilibrium at different depths. The alpha particles and 
heavy nuclei have short ranges in tissue and attain equilibrium at shallower 
depths. The low LET, recoil protons attain equilibrium at a depth of 16 mm 
(Binns, 1993). In the build up region, the average LET of the secondary charged 
particles decreases with depth. Once the charged particle equilibrium is 
established, the peak 6/5 ratio remains constant. Hence the peak 6/5 ratio 
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Figure 4. 7: Peak 6/5 ratio as afunction of depth in the build up region. Extrapolation 
chamber measurements are also plotted 
4.5 Peak 6/5 ratio in beam profile measurements 
The softening of the neutron beam as a result of beam scattering and the sharp 
increased in the photon component both affect the quality of the therapy beam in 
the penumbra region. In the following experiments, we aim to detennine the 
changes in the peak 6/5 ratio with off-axis distance. 
In the fIrst experiment, the TLD chips were irradiated in a 5.5 cm x 5.5 cm field 
in the central axis of the beam and at distances of 1 - 5 cm off-axis. The peak 6/5 
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ratio as a function of off-axis distance is shown in figure 4.8. The peak 6/5 ratio 
is fairly constant within the irradiation field and seems to increase with off-axis 
distance. To extend this study to a wider off-axis distances, chips were irradiated 
in a second experiment each at distances up to 9 cm off-axis. Four chips were 
irradiated at each off-axis distance. The peak 6/5 ratio remains constant within 
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Figure 4.8: Peak 6/5 ratio versus off-axis distance/or a 5.5 cm x 5.5 cmfield 
In the penumbra region the gamma components rises sharply (Jones et ai., 1995 
and Binns, 1993). This effect lowers the peak 6/5 ratio since the peak 6/5 ratio 
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measured in a cobalt-60 beam is smaller than in a neutron, i.e. high LET, beam. 
However, the neutron component in the penwnbra region consists of scattered 
lower energy neutrons that possess a higher average LET which increases the 
peak 6/5 ratio in this region. Hence, in the penwnbra region two physical 
processes occur of which one lowers the peak 6/5 ratio whereas the other 
increases the peak 6/5 ratio. A rise in the peak 6/5 ratio is observed in the 
penwnbra region which indicates that the change in the neutron component's 
composition is the dominating effect in terms of the peak 6/5 ratio. 
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Figure 4. 9: Peak 6/5 ratio outside beam axis. 
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The peak 6/5 ratio in the penumbra region can be divided into a neutron and 
. (P6J - (P6J (P6J gamma component, - - .ne + - .re' 
p5 comb. p5 n p5 r 
where (~:l.. is the combined, i.e. measured peak 6/5 ratio, (~:J. and 
(~:l are the peak 6/5 ratios due 10 the neutron and gamma components, and 
l1c and ¥c are the neutron and gamma components respectively. The gamma 
component has been measured in the penumbra region (Jones et al., 1995 and 
Binns, 1993), which allows the determination of l1c and ¥c as a fimction of off-
axis distance. The (~: 1 value can be determined from TLD-700 irradiations in 
a cobalt-60 beam. This allows the calculation of the (~:l ratio as a function of 
off-axis distance. Figure 4.10 shows the results of this evaluation. Accompanying 
microdosimetry measurements would allow the determination of (~: J. ratio as a 
-
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Figure 4. 10: The variation of peak 6/5 ratio with off-axis distance. The gamma 
component (Jones et al., 1992) is also plotted against off-axis distance. 
The peak 615 ratio measurements follow the expected increase in the average 
LET in the penumbra region. These measurements in combination with those 
done in the built up region allow the conclusion that the peak 615 ratio as 
measured with TLD-700 gives an indication of the relative beam quality. 
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Chapter 5: Summary and conclusion 
In this proje<;:t, TLD-700 chips have been employed for absorbed dose 
measurements in a p( 66)lBe therapeutic neutron beam. After careful chip 
selection, the detectors were calibrated in the neutron beam and the chip specific 
calibration factors were determined, which were used in all subsequent 
measurements. 
The dose non-linearity was determined in the dose ranging from 1 Gy to 3 Gy in 
the p( 66)lBe neutron beam. Saturation was observed in peak 5 and supralinearity 
was observed in peak 6. The dose non-linearity correction equations were derived 
for peak 5 and peak 6 separately and were used to correct the dose non-linearity 
in subsequent measurements. The TLD sensitivity at depth in the phantom was 
determined by irradiating TLD chips at different depths in the phantom. The peak 
5 sensitivity was found to be constant with depth. Measurements of the beam 
profile were performed. Changes in the TLD sensitivity relative to ionisation 
chamber measurements were observed in the penumbra region where the beam 
quality changes. 
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Actual in-vivo dose measurements were performed in the direct neutron field 
after characterising the TLD chips in the phantom. In-vivo measurements were 
performed on seven patients (9 fields). Entrance in-vivo dose measurements were 
measured under 2 mm thick AI50 tissue equivalent plastic built up. The patient 
entrance doses determined with TLDs are in good agreement with the treatment 
plan doses (Table 3.2). Maximal deviations of 3.2 % were detected and a 
systematic difference of 1.7 % exists between the TLD measurements and the 
treatment plan doses. Exit doses were measured on six patients (7 fields). 
Discrepancies up to -7.3 % were detected on the exit side and a systematic 
difference of -5.1 % was apparent between the TLD measurements and the 
treatment plan exit doses (Table 3.3). 
The glow peak 6 over 5 ratio was determined in our beam with the aim of 
extracting further useful information from the TLD glow curve. This ratio was 
found to be high at the surface of the phantom, it decreases in the built up region 
remains constant with depth thereafter. The peak 6/5 ratio was found to increase 
with off axis distance. The peak 6/5 ratio changes in areas where qualitative 
changes in the therapy beam occur and can be used as an indication of the 
relative beam quality, 
In conclusion, we demonstrated the feasibility of using TLD-700 chips as an in-
vivo dosimeter in fast neutron therapy beams for entrance and exit dose 
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measurements. These detectors can also be useful to determine relative changes 
in the beam quality. 
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